Treatment-related AEs (≥ 3 participants)*
| Event type | 25 mg/240 mg† N=55 |
| Nausea | 14 (25.5) [19] |
| Fatigue | 12 (21.8) [17] |
| Diarrhea | 10 (18.2) [16] |
| Decreased appetite | 8 (14.5) [9] |
| Pyrexia | 7 (12.7) [8] |
| Pruritus | 6 (10.9) [6] |
| Alanine aminotransferase increased | 5 (9.1) [6] |
| Aspartate aminotransferase increased | 4 (7.3) [6] |
| Chills | 3 (5.5) [3] |
| Pneumonitis | 3 (5.5) [3] |
*50 mg pixatimod/240 mg nivolumab data not presented as only three participants were recruited.
†For any given AE, the results are presented as the number of participants with the event: n, the proportion of participants with the event: (%), and the number of events: [e].
AEs, adverse events.